{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-150435","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2024-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.985053+00:00","generated_at":"2026-06-01T07:32:24.404662+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"XOMA to receive $8.1M from Viracta after Day One sells PRV for $108M","bullets":["Day One Biopharmaceuticals sold a priority review voucher for $108M after FDA approval of OJEMDA.","XOMA is entitled to $8.1M from Viracta under a March 2021 agreement covering tovorafenib milestones.","The PRV sale proceeds trigger event-based economics payable to XOMA.","Funds represent a portion of the PRV proceeds passed through from Day One to Viracta."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-150435","json":"https://secwatch.observer/filing/0001193125-24-150435.json","markdown":"https://secwatch.observer/filing/0001193125-24-150435.md","text":"https://secwatch.observer/filing/0001193125-24-150435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312524150435/0001193125-24-150435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312524150435/d839143d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:32:24.404662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}